CAMBRIDGE, Mass., April 26,
2023 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced the acceptance of clinical abstracts
for multiple programs across its precision therapy portfolio at the
2023 American Society of Clinical Oncology (ASCO) Annual Meeting,
June 2 to 6. The presentations
showcase Blueprint Medicines' next wave of therapeutic candidates
in its robust clinical pipeline, and highlight ongoing progress as
the company seeks to pioneer innovative combination strategies and
advance development of its programs into earlier lines of
treatment.
The datasets to be reported at the ASCO Annual Meeting
include:
- Results from the ongoing dose escalation part of the VELA trial
of BLU-222 in breast cancer and other cancers vulnerable to CDK2
inhibition, showing evidence of monotherapy safety and pathway
modulation.
- Updated results from the dose escalation part of the SYMPHONY
trial showing the safety and tolerability of BLU-945 as a
monotherapy and in combination with osimertinib in patients with
late-line, EGFR-mutant non-small cell lung cancer (NSCLC).
- Results from the ongoing dose escalation part of the CONCERTO
trial of BLU-451 in EGFR exon 20 insertion-positive NSCLC showing
early safety and clinical activity.
"These upcoming presentations reflect important clinical
progress toward realizing the promise of our innovative precision
therapies to help address complex medical needs in lung and breast
cancer, leveraging our scientific and development expertise with
the goal of overcoming traditional limitations of targeted
therapy," said Becker Hewes, M.D., Chief Medical Officer at
Blueprint Medicines. "Collectively, the datasets represent another
step toward achieving our 2027 Blueprint for Precision at Scale –
our five-year growth strategy to reach broad patient populations
through the development of transformative precision therapies."
The accepted abstracts are listed below, and abstract titles are
available today on the ASCO conference website:
meetings.asco.org.
Data Presentations
Poster Presentation Title: BLU-222, an oral, potent and
selective CDK2 inhibitor, in patients with advanced solid tumors:
phase 1 monotherapy dose escalation
Session Title: Developmental Therapeutics—Molecularly
Targeted Agents and Tumor Biology
Session Date & Time: Saturday,
June 3, 2023 from 8:00 a.m. —
11:00 a.m. CT (9:00 a.m. — 12:00 p.m.
ET)
Abstract Number: 3095
Location: Hall A
Poster Presentation Title: Emerging phase 1 data of
BLU-451 in advanced NSCLC with EGFR exon 20 insertions
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date & Time: Sunday, June
4, 2023 from 8:00 a.m. —
11:00 a.m. CT (9:00 a.m. — 12:00 p.m.
ET)
Abstract Number: 9064
Location: Hall A
Short Oral Presentation Title: BLU-945 monotherapy
and in combination with osimertinib (OSI) in previously treated
patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2
SYMPHONY study
Session Title: Rapid Abstract Session: Lung Cancer
Session Date & Time: Monday, June
5, 2023 from 11:30 a.m. —
12:30 p.m. CT (12:30 p.m. — 1:30 p.m.
ET)
Abstract Number: 9011
Location: S406
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company
that invents life-changing therapies for people with cancer and
blood disorders. Applying an approach that is both precise and
agile, we create medicines that selectively target genetic drivers,
with the goal of staying one step ahead across stages of disease.
Since 2011, we have leveraged our research platform, including
expertise in molecular targeting and world-class drug design
capabilities, to rapidly and reproducibly translate science into a
broad pipeline of precision therapies. Today, we are delivering our
approved medicines to patients in the United
States and Europe, and we are globally advancing multiple
programs for systemic mastocytosis, lung cancer, breast cancer and
other genomically defined cancers, and cancer immunotherapy. For
more information, visit www.BlueprintMedicines.com and
follow us on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans, strategies, timelines and expectations for
Blueprint Medicines' current or future approved drugs and drug
candidates, including the results of ongoing clinical trials; the
potential benefits of any of Blueprint Medicines' current or future
approved drugs or drug candidates in treating patients; and
Blueprint Medicines' financial performance, growth strategy, goals
and anticipated milestones, business plans and focus. The words
"aim," "may," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation: the COVID-19 pandemic may impact Blueprint Medicines'
business, operations, strategy, goals and anticipated milestones,
including ongoing and planned research and discovery activities,
Blueprint Medicines' ability to conduct ongoing and planned
clinical trials; the risk of delay of any current or planned
clinical trials or the development of Blueprint Medicines' current
or future drug candidates; risks related to Blueprint Medicines'
ability to successfully demonstrate the safety and efficacy of its
drug candidates and gain approval of its drug candidates on a
timely basis, if at all; preclinical and clinical results for
Blueprint Medicines' drug candidates may not support further
development of such drug candidates either as monotherapies or in
combination with other agents or may impact the anticipated timing
of data or regulatory submissions; the timing of the initiation of
clinical trials and trial cohorts at clinical trial sites and
patient enrollment rates may be delayed or slower than anticipated;
actions of regulatory agencies may affect the initiation, timing
and progress of clinical trials; risks related to Blueprint
Medicines' ability to obtain, maintain and enforce patent and other
intellectual property protection for its products and current or
future drug candidates it is developing; and the success of
Blueprint Medicines' current and future collaborations, financing
arrangements, partnerships or licensing arrangements. Any
forward-looking statements contained in this press release
represent Blueprint Medicines' views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Except as required by law, Blueprint Medicines
explicitly disclaims any obligation to update any forward-looking
statements.
Trademarks
Blueprint Medicines and associated logos are trademarks
of Blueprint Medicines Corporation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-new-clinical-data-across-broad-precision-therapy-pipeline-at-2023-asco-annual-meeting-301807634.html
SOURCE Blueprint Medicines Corporation